A phase II study of intravenous DX-8951f [exatecan] administered daily for five days every three weeks to patients with hepatocellular carcinoma
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Exatecan (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 15 May 2012 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
- 11 Sep 2005 New trial record.